# A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

> **NCT02283177** · PHASE2 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Newly Diagnosed AML With FLT3 Activating Mutations

## Interventions

- **DRUG:** crenolanib
- **DRUG:** cytarabine
- **DRUG:** daunorubicin
- **DRUG:** idarubicin

## Key facts

- **NCT ID:** NCT02283177
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283177, "A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02283177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*